TABLE 3.
Assessment of biochemical parameters—azotemia (a), and levels of serum creatinine (b), creatine phosphokinase (CPK; c), and transaminases (d, e)—at baseline, after 4-week treatment with NanoBEO and at the end of the follow-up period. The reference values, depending on the laboratory, are reported in brackets.
| Azotemia (mg/dL) | |||
|---|---|---|---|
| Patient ID | Baseline | Treatment (week 4) | Follow-up (week 8) |
| D02 | 42.00 (17.00–43.00) | 53.00 (17.00–43.00) | 46.7 (17.00–43.00) |
| D04 | 74.00 (17.00–43.00) | 111.00 (17.00–43.00) | 82.9 (17.00–43.00) |
| D06 | 77.00 (17.00–43.00) | 54.00 (17.00–43.00) | 74.00 (17.00–43.00) |
| D08 | 39.00 (17.00–43.00) | 46.00 (17.00–43.00) | 32.00 (17.00–43.00) |
| D13 | ____ | 95.00 (17.00–43.00) | 79.00 (17.00–43.00) |
| D14 | 29.00 (17.00–43.00) | 41.00 (17.00–43.00) | 66.00 (17.00–43.00) |
| D16 | 48.00 (10.00–55.00) | 41.00 (10.00–55.00) | 50.00 (10.00–55.00) |
| D19 | 61.00 (10.00–55.00) | 45.00 (10.00–55.00) | 46.00 (10.00–55.00) |
| D20 | 78.00 (10.00–55.00) | 95.00 (10.00–55.00) | 110.00 (10.00–55.00) |
| D22 | 35.00 (17.00–43,00) | 33.00 (17.00–43.00) | 34,3 (17.00–43.00) |
| D23 | 55.00 (17.00–43.00) | 31.00 (17.00–43.00) | 49.1 (17.00–43.00) |
| D27 | 41.00 (20.00–50.00) | 29.00 (10.00–50.00) | 35.00 (10.00–50.00) |
| D28 | 49.00 (10.00–50.00) | 53.00 (10.00–50.00) | 58.00 (10.00–50.00) |
| D31 | 37.00 (10.00–50.00) | 44.00 (10.00–50.00) | 37.00 (10.00–50.00) |
| Serum creatinine (mg/dL) | |||
|---|---|---|---|
| Patient ID | Baseline | Treatment (week 4) | Follow-up (week 8) |
| D02 | 0.83 (0.66–1.09) | 0.92 (0.66–1.09) | 0.87 (0.66–1.09) |
| D04 | 1.4 (0.66–1.09) | 1.62 (0.66–1.09) | 1.48 (0.66–1.09) |
| D06 | 1.23 (0.66–1.09) | 1.15 (0.66–1.09) | 1.14 (0.66–1.09) |
| D08 | 0.93 (0.66–1.09) | 1.09 (0.66–1.09) | 0.81 (0.66–1.09) |
| D13 | ____ | 1.7 (0.66–1.09) | 1.77 (0.66–1.09) |
| D14 | 0.78 (0.66–1.09) | 0.9 (0.66–1.09) | 0.9 (0.66–1.09) |
| D16 | 0.88 (0.60–1.30) | 0.84 (0.50–0.90) | 0.84 (0.50–0.90) |
| D19 | 0.95 (0.60–1.30) | 0.82 (0.50–0.90) | 0.89 (0.50–0.90) |
| D20 | 1.42 (0.60–1.30) | 1.40 (0.50–0.90) | 1.63 (0.50–0.90) |
| D22 | 0.64 (0.66–1.09) | 0.68 (0.66–1.09) | 0.77 (0.66–1.09) |
| D23 | 0.84 (0.66–1.09) | 0.74 (0.66–1.09) | 0.95 (0.66–1.09) |
| D27 | 1.19 (0.50–0.90) | 0.99 (0.60–1.30) | 1.14 (0.60–1.30) |
| D28 | 0.59 (0.70–1.40) | 0.68 (0.70–1.40) | 0.57 (0.70–1.40) |
| D31 | 0.73 (0.60–1.30) | 0.77 (0.60–1.30) | 0.67 (0.60–1.30) |
| Creatine phosphokinase (CPK; IU) | |||
|---|---|---|---|
| Patient ID | Baseline | Treatment (week 4) | Follow-up (week 8) |
| D02 | 42 (0–145) | 59 (0–145) | 66 (0–145) |
| D04 | 28 (0–145) | 20 (0–145) | 19 (0–145) |
| D06 | 58 (0–145) | 27 (0–145) | 31 (0–145) |
| D08 | 19 (0–145) | 25 (0–145) | 20 (0–145) |
| D13 | 93 (0–145) | 88 (0–145) | 100 (0–145) |
| D14 | 30 (0–145) | 35 (0–145) | 73 (0–145) |
| D16 | ____ | ____ | ____ |
| D19 | 77 (26–192) | 57 (26–192) | 49 (26–192) |
| D20 | 42 (26–192) | 34 (26–192) | 44 (26–192) |
| D22 | 30 (0–145) | 40 (0–145) | 25 (0–145) |
| D23 | 46 (0–145) | 50 (0–145) | 53 (0–145) |
| D27 | ____ | 16 (34–145) | 15 (34–145) |
| D28 | 47 (46–171) | 46 (46–171) | 39 (46–171) |
| D31 | 36 (34–145) | 15 (34–145) | 15 (34–145) |
| Serum GOT transaminase (IU) | |||
|---|---|---|---|
| Patient ID | Baseline | Treatment (week 4) | Follow-up (week 8) |
| D02 | 20 (11–34) | 23 (11–34) | 17 (11–34) |
| D04 | 15 (11–34) | 16 (11–34) | 11 (11–34) |
| D06 | 16 (11–34) | 17 (11–34) | 18 (11–34) |
| D08 | 16 (11–34) | 17 (11–34) | 15 (11–34) |
| D13 | ____ | 39 (11–34) | 40 (11–34) |
| D14 | 10 (11–34) | 16 (11–34) | 65 (11–34) |
| D16 | 21 (0–33) | 14 (0–33) | 15 (0–33) |
| D19 | 16 (0–33) | 12 (0–33) | 11 (0–33) |
| D20 | 41 (0–33) | 31 (0–33) | 28 (0–33) |
| D22 | 12 (11–34) | 13 (11–34) | 11 (11–34) |
| D23 | 19 (11–34) | 30 (11–34) | 20 (11–34) |
| D27 | 16 (0–31) | 22 (5–38) | 12 (5–38) |
| D28 | 13 (5–38) | 21 (5–38) | 12 (5–38) |
| D31 | 28 (5–38) | 40 (5–38) | 18 (5–38) |
| Serum GPT transaminase (IU) | |||
|---|---|---|---|
| Patient ID | Baseline | Treatment (week 4) | Follow-up (week 8) |
| D02 | 11 (7–41) | 14 (7–41) | 9 (7–41) |
| D04 | 4 (7–41) | 4 (7–41) | 3 (7–41) |
| D06 | 9 (7–41) | 12 (7–41) | 10 (7–41) |
| D08 | 13 (7–41) | 9 (7–41) | 7 (7–41) |
| D13 | ____ | 21 (7–41) | 24 (7–41) |
| D14 | 9 (7–41) | 15 (7–41) | 14 (7–41) |
| D16 | 7 (0–32) | 8 (0–32) | 16 (0–32) |
| D19 | 9 (0–32) | 11 (0–32) | 10 (0–32) |
| D20 | 19 (0–32) | 14 (0–32) | 10 (0–32) |
| D22 | 7 (7–41) | 10 (7–41) | 7 (7–41) |
| D23 | 7 (7–41) | 23 (7–41) | 8 (7–41) |
| D27 | 10 (0–31) | ____ | 15 (0–49) |
| D28 | 12 (0–49) | 23 (0–49) | 14 (0–49) |
| D31 | 34 (0–49) | 45 (0–49) | 19 (0–49) |
GPT: glutamic-pyruvic transaminase (also known as alanine aminotransferase [ALT]).
GOT: glutamic-oxaloacetic transaminase (also known as aspartate aminotransferase [AST]).